12,372 trials
HIV-1
Primary: Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF) — 139.9; 200.6 h*ng/mL
Asthma
Primary: Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity) — 3.9534; 3.4964; 0.8191 L*hr — p=<0.0001
Breast Cancer
Primary: Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation — 94.10; 92.75 Percent Probability — p=0.8270
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16 — 56.39; 29.41 Percentage of participants…
Inflammation and Pain Associated With Cataract Surgery
Primary: Number of Participants With Anterior Chamber Cell Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population…
Pain, Postoperative
Primary: SPI24 — 85.0; 106.8 units on a scale
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
Pain, Postoperative
Primary: SPI24 — 88.3; 116.2 units on a scale
Central Precocious Puberty
Primary: Luteinizing Hormone (LH) — 0.88; 0.53; 0.07; 0.50 MIU/ML
Fungal Infection · Hematopoietic and Lymphoid Cell Neoplasm
Primary: 42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections (IFI) — 1.4; 1.4 percentage of patients
Asthma
Primary: Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge — 0.822; 6.468 Percent — p=0.0208
Sickle Cell Disease
Primary: Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24 — 30; 46; 6 Participants
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…
Cardiac Disease
Primary: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader — 5.70; 5.88; 5.03; 6.08 Percent Ejection Fraction — p=0.358
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™ — 9.8; 5.6; 55.0; 41.4 Percentage of Participants — p=0.043